Search

everythinglearnresearchcommunity

for

Search:↓

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

Testosterone therapy can help improve sexual desire and function in postmenopausal women but may cause side effects and is not FDA-approved for this use.

Androgen therapy might help some women with low libido, but it has risks and should be used carefully.

Dihydrotestosterone makes arteries stiffer in female mice by reducing estrogen receptor expression.

Most treatments for Frontal Fibrosing Alopecia are ineffective, but early anti-inflammatory therapy may help and the condition may stabilize over time.

Androgens play a role in female sexual function, and testosterone therapy can help women with low sexual desire, but more research is needed on treatments and long-term safety.

Testosterone therapy can improve sexual desire and function in postmenopausal women but should be used cautiously and not based solely on testosterone levels.

Testosterone therapy can help postmenopausal women with low sexual desire but needs more safety research and should be used with estrogen therapy.

Testosterone therapy can help with androgen deficiency in women but should be used with caution and monitoring due to potential risks.

Testosterone therapy can help improve sexual function, mood, and bone density in women with low androgen levels, but more research is needed on long-term safety.

Testosterone therapy seems safe for postmenopausal women for a few years, but more research is needed for long-term effects.

Short-term testosterone therapy in women seems safe with few mild side effects, but long-term effects need more research.

Minoxidil, finasteride, and low-level laser light therapy are effective FDA-approved treatments for hair loss.

The conclusion is that PCOS is caused by ovarian sensitivity to hormones and disrupted hormone control, possibly due to ovarian factors, and more research is needed.

Testosterone replacement may help some postmenopausal women with symptoms like fatigue and low libido, but more research is needed to fully understand its effects.

Sex hormones, especially androgens, play a key role in causing acne.

AGA treatments like minoxidil and LLLLT are safe and effective for gender minority patients.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

The document concludes that scalp disorders can be treated with hair washing, specific shampoos, medications, and sometimes surgery or hair transplants, but hereditary baldness is untreatable.

The safety and effectiveness of gender-affirming treatments for children are uncertain, with potential long-term risks like infertility.

Estrogens are key for bone growth spurts in both boys and girls and affect growth into adulthood.

Women with PCOS may have a higher risk of respiratory and ear infections due to slower nasal mucociliary clearance.

Testosterone Replacement Therapy can improve sexual health in postmenopausal women with low sexual desire, but more research is needed on its long-term effects.

Hormonal imbalances during menopause may significantly contribute to Frontal Fibrosing Alopecia.

DHEA did not improve sexual function, well-being, or menopausal symptoms in postmenopausal women with low libido but caused side effects like acne and increased facial hair.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.

Chromosomal differences affect how muscle cells respond to testosterone.